To date, there is no vaccine and no specific antiviral agent against SARS-CoV-2. Because of hospital saturation, controversial drug efficiency and the risk of medicinal shortage, there is an urgent need for alternative treatment options. Passive (plasmapheresis) and active immunization (vaccine) approaches aim to provide or elicit a protective humoral immune response against SARS-CoV-2. This project aims to develop a high throughput assay to measure the neutralizing activity of COVID-19 patients. It will help characterize the antibody response against SARS-CoV-2, and select the sera with hi...